Division of Novartis AG
Latest From AveXis Inc.
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.
With top-line data showing efficacy in type 1 SMA patients, risdiplam may be able to obtain a label that would address significantly more patients than Novartis’ Zolgensma. Final efficacy data will show how drug’s efficacy compares to Biogen’s Spinraza.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: There was no big M&A, but biopharma CEOs discussed deals they're pursuing. Also, Novartis's Zolgensma reimbursement insights, Sarepta's third DMD filing, Bristol's post-merger progress and more highlights.
- Gene Therapy, Cell Therapy
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Novartis AG
- Senior Management
David Lennon, PhD, Pres.
Brian K Kaspar, PhD, CSO
Andrew Knudten, SVP, Tech. Operations & CTO
Rick Modi, SVP, CBO
James J L’Italien, PhD, SVP, Chief Reg. & Quality Officer
- Contact Info
Phone: (847) 572-8280
2275 Half Day Rd.
Bannockburn, IL 60015
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.